Form 4: CG Oncology Director Leonard Post Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 28, 2025, Leonard Post, a director of CG Oncology, exercised a stock option to acquire 1,000 shares of common stock at a price of $0.60 per share.
- Simultaneously, Post sold 1,000 shares of CG Oncology common stock at a price of $30.76 per share.
- The sale was executed under a Rule 10b5-1 trading plan adopted on September 6, 2024.
- Following these transactions, Post directly owns 129,077 shares of CG Oncology common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of insider trading activity under a pre-arranged plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the director is selling shares in a pre-planned manner to avoid accusations of trading on inside information. It is common for executives to use these plans.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 04/28/2025 | Date of stock option exercise and share sale |
| 04/29/2025 | Date of signature on the SEC Form 4 filing |
| 07/08/2028 | Expiration date of the Director Stock Option |
Keywords
CG Oncology, Leonard Post, Stock Option, Rule 10b5-1, Director, Share Sale, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.